Final height in girls with Turner’s syndrome treated with once or twice daily growth hormone injections


Arch. Dis. Child. 1999;80;36-41

Updated information and services can be found at:
http://adc.bmj.com/cgi/content/full/80/1/36

These include:

References
This article cites 25 articles, 12 of which can be accessed free at:
http://adc.bmj.com/cgi/content/full/80/1/36#BIBL

6 online articles that cite this article can be accessed at:
http://adc.bmj.com/cgi/content/full/80/1/36#BIBL

Rapid responses
You can respond to this article at:
http://adc.bmj.com/cgi/eletter-submit/80/1/36

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Other Endocrinology (621 articles)
Other Pediatrics (1862 articles)

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to Archives of Disease in Childhood go to:
http://www.bmjournals.com/subscriptions/
Final height in girls with Turner’s syndrome treated with once or twice daily growth hormone injections


Abstract

Objectives—To study final height in girls with Turner’s syndrome treated with once or twice daily injections of growth hormone (GH) in combination with low dose ethinyl oestradiol.

Design—Until final height was reached, the effect of fractionated subcutaneous injections given twice daily was compared with once daily injections of a total GH dose of 6 IU/m²/day. Twice daily injections were given as one third in the morning and two thirds at bedtime. All girls concurrently received low dose oestradiol (0.05 µg ethinyl oestradiol/kg/day, increased to 0.10 µg/kg/day after 2.25 years). Patients—Nineteen girls with Turner’s syndrome aged ≥ 11 years (mean (SD) 13.6 (1.7) years).

Measurements—To determine final height, we assessed the difference between the attained final height and the final height predictions at the start of treatment. These final height predictions were calculated using the Bayley-Pinneau (BP) prediction method, the modified projected adult height (mPAH), the modified index of potential height (mIPPHₐₚ), and the Turner’s specific prediction method (PTSh).

Results—The gain in final height (mean (SD)) was not significantly different between the once daily and the twice daily regimens (7.6 (2.3) vs 8.1 (3.2) cm). All girls exceeded their adult height prediction (range, 1.6–12.3 cm). Thirteen of the 19 girls had a final height gain > 5.0 cm. Mean (SD) attained final height was 155.5 (5.4) cm. A “younger bone age” at baseline and a higher increase in height standard deviation score for chronological age (Dutch–Swedish–Danish references) in the first year of GH treatment predicted a higher final height gain after GH treatment.

Conclusions—Division of the total daily GH dose (6 IU/m²/day) into two thirds in the evening and one third in the morning is not advantageous over the once daily GH regimen with respect to final height gain. Treatment with a GH dose of 6 IU/m²/day in combination with low dose oestrogens can result in a significant increase in adult height in girls with Turner’s syndrome, even if they start GH treatment at a relatively late age.

Keywords: Turner’s syndrome; growth hormone treatment; final height; growth

Growth failure and subsequently short adult stature is one of the main features in Turner’s syndrome.1 2 It has been shown that short stature, independent of aetiology, can be associated with psychosocial problems.3 Growth hormone (GH) treatment improves height velocity and adult height in most girls with Turner’s syndrome.4 5 6 13 14 Studies in patients with Turner’s syndrome have shown that the initial growth response to GH treatment is dependent on the dose and frequency of administration.4 6 13 14 To improve the growth response, intramuscular injections three times a week have been replaced by a once daily subcutaneous regimen.13 14 However, just as in normal growing girls,15 spontaneous GH secretion in Turner’s syndrome is characterised by a large peak soon after falling asleep and the occurrence of several other peaks during the course of a 24 hour period.16 17 Thus, a more frequent injection regimen might improve the growth response, as has also been suggested by a study in GH deficient patients.18

In this study, an attempt was made to mimic the normal pulsatile GH secretion pattern more closely. The total GH dose of 6 IU/m² body surface/day was divided into two thirds in the evening and one third in the morning in one group of patients. The other group received the same total GH dose once daily, in the evening. A total dose of 6 IU/m²/day was chosen instead of the more commonly used 4 IU/m²/day because an earlier study has shown that on the latter dose the growth response in a somewhat older subgroup of girls with Turner’s syndrome was poorer than in younger girls.19 Two year results were described earlier by our group.20 We now report follow up until final height comparing the effects of twice daily and once daily GH administration in 19 girls with Turner’s syndrome aged 11 years or over concurrently receiving low dose ethinyl oestradiol.

Patients and methods

STUDY GROUP
We studied 19 previously untreated girls with Turner’s syndrome, confirmed by lymphocyte

Department of Paediatrics, Division of Endocrinology, Sophia Children’s Hospital, Dr. Molewaterplein 60, 3015 GJ Rotterdam, Netherlands
Th C J Sas
S M P F de Muinck Keizer-Schrama
A van Teunenbroek
A C S Hokken-Koelega
S L S Drop

Department of Biostatistics, Erasmus University Rotterdam, Netherlands
Th Stijnen

Catharina Hospital, Eindhoven, Netherlands
J J J Waclens

Leiden University Medical Centre, Leiden, Netherlands
G G Massa

Emma Children’s Hospital, Academic Medical Centre, Amsterdam, Netherlands
Th Vulsma

Academic Hospital, Maastricht, Netherlands
W J Gerver

Juliana Children’s Hospital, The Hague, Netherlands
H M Reeser

Free University Hospital, Amsterdam, Netherlands
H E Delemarre-van de Waal

Wilhelmina Children’s Hospital, Utrecht, Netherlands
M Jansen

Correspondence to:
Dr Sas.

Accepted 10 August 1998
chromosomal analysis. Before treatment, 10 girls were enrolled in a 10 week (crossover design) 24 hour GH profile study, as described earlier.23 In brief, they started taking ethinyl oestradiol (0.05 µg/kg/day) four weeks before they were divided randomly into the once daily or twice daily GH injection groups. GH treatment was then administered for two weeks. Following a washout interval of two weeks, GH treatment was resumed for another period of two weeks, using the alternative injection frequency. The additional nine girls followed the same schedule without 24 hour GH profile testing. After a second randomisation, which was carried out independently from the first randomisation, all 19 girls entered the present study immediately after completion of the 10 week design. At the start of the crossover study, all girls had Tanner puberty stage B1,25 were aged 11 years or over, and had a Tanner and Whitehouse RUS (radius, ulna, short bones) bone age (RUS BA)26 of less than 13.5 years. Exclusion criteria were: associated endocrine and/or metabolic disorders, growth failure caused by other disorders or emotional deprivation, hydrocephalus, and previous use of drugs that might interfere with GH treatment. Written informed consent was obtained from the girls and their parents. The study protocol was approved by the ethics committee of each participating centre.

STUDY DESIGN

After stratification for RUS BA and height standard deviation score for chronological age (HSDSCA), the girls were divided randomly into two GH injection frequency groups. One group (n = 9) received 6 IU/m² body surface once daily, in the evening. A second group (n = 10) received the same total GH dose divided into one third in the morning and two thirds at bedtime. GH (r-hGH Norditropin; Novo Nordisk A/S, Bagsvaerd, Denmark) was injected by a pen injection system (Nordiject 24; Novo Nordisk A/S). Compliance was carefully monitored. GH treatment was stopped when height velocity had decreased to < 1 cm/six months. The figure for final height was recorded six months after the end of treatment. From the start of the 10 week crossover study, all girls received 0.05 µg ethinyl oestradiol/kg/day, once daily. After the first 2.25 years of GH treatment, the dose of ethinyl oestradiol was increased to 0.10 µg/kg/day and cyclic progestagens were added.

GROWTH EVALUATION

Height (H) was measured at baseline and three monthly until final height was reached. Heights were determined according to Cameron,27 using a Harpenden stadiometer; four measurements were made on each visit by two trained observers (AvT and later ThS). Height was expressed as HSDSCA using the Roede en van Wieringen references for healthy Dutch girls (HSDSCA (RvW))18 and the Dutch–Swedish–Danish Turner’s references (HSDSCA (DSD)).15 At final height, HSDSCA (DSD) was calculated by using the mean height (146.95 cm) and the standard deviation (6.37 cm) of untreated girls with Turner’s syndrome (DSD) references of 21 years of age. Target height (TH) was adapted from Dutch reference data28 with the addition of 3 cm for secular trend: TH = ½(Hmatheral + Hfatheral – 12 cm) + 3 cm. Pubertal stages were assessed according to Tanner.13 Bone age was determined by the same two investigators (AvT and later ThS) according to Tanner and Whitehouse RUS BA26 and to Greulich and Pyle (GP BA).29 To determine final height gain, we assessed the difference between the attained final height and the final height predictions at start of treatment. These final height predictions were calculated by using the Bayley-Pinneau (BP) prediction method,30 the modified projected adult height (mPAH),31 32 the modified index of potential height (mIPH),32 33 and the recently developed Turner’s specific prediction method (PTS<sub>RUS</sub>), based on regression coefficients for height, chronological age, and RUS BA.32 The latter three methods are based on Dutch Turner’s references, as described previously.26

Before any treatment, all girls underwent a GH provocation test by infusion of arginine (0.5 g/kg body weight in 30 minutes). In addition, blood was taken for the determination of insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3), and GH binding protein (GHBP) at the start of our study (pretreatment) and at six and 18 months after it started. The methods and the results of these measurements were described previously.24 25 34–37

STATISTICS

Results are expressed as mean (SD) unless indicated otherwise. The Student’s t test or the χ² test were used to test differences between groups. Student’s paired sample test was used for comparing means within groups. Correlations were tested with Pearson’s linear correlation coefficient. To compare final height between the once daily and twice daily groups, a multiple linear regression analysis adjusted for baseline variables was performed. For this analysis, RUS BA and the average of the four final height predictions were chosen as baseline variables. In the search for determinants of treatment success (final height gain = attained final height minus predicted final height), multiple linear regression analyses, adjusted for treatment group, were done. For each possible predictive factor, separate analyses were performed. Possible predictive factors for final height gain after GH treatment were at baseline: chronological age, RUS BA, HSDSCA (DSD), target height, concentrations of IGF-I, IGFBP-3, IGF-I to IGFBP-3 ratio, GHBP, and the maximal GH value during a provocation test; after the first six months of GH treatment: the change from baseline of IGF-I, IGFBP-3, IGF-I to IGFBP-3 ratio, GHBP, and the maximal GH value during a provocation test; after the first six months of GH treatment: the change from baseline of IGF-I, IGFBP-3, IGF-I to IGFBP-3 ratio and GHBP levels; and in the first year of GH treatment: the change in HSDSCA (DSD). A p value < 0.05 was considered significant.
Table 1  Pretreatment clinical data

<table>
<thead>
<tr>
<th></th>
<th>Once daily group (n = 9)</th>
<th>Twice daily group (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA (years)</td>
<td>13.3 (1.7)</td>
<td>13.8 (1.8)</td>
</tr>
<tr>
<td>RUS BA (years)</td>
<td>12.2 (1.0)</td>
<td>12.7 (0.9)</td>
</tr>
<tr>
<td>GP BA (years)</td>
<td>11.4 (0.6)</td>
<td>11.8 (0.8)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>134.3 (5.1)</td>
<td>140.8 (7.9)</td>
</tr>
<tr>
<td>HSDSCA (RvW)</td>
<td>−3.7 (1.3)</td>
<td>−3.1 (1.2)</td>
</tr>
<tr>
<td>HSDS (DSD)</td>
<td>0.2 (1.1)</td>
<td>1.1 (1.3)</td>
</tr>
<tr>
<td>Target height (cm)</td>
<td>166.5 (4.5)</td>
<td>168.3 (6.3)</td>
</tr>
<tr>
<td>Karyotype</td>
<td>45,X</td>
<td>8</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>2</td>
</tr>
</tbody>
</table>

Results are mean (SD).

CA, chronological age; BA, bone age; RUS, radius, ulna, short bones; GP, Greulich and Pyle; HSDSCA, height standard deviation score for chronological age; RvW, Roede van Wieringen references for healthy Dutch girls; DSD, Dutch–Swedish–Danish references for girls with Turner’s syndrome.

Table 2  Predictions of adult height at start of growth hormone treatment

<table>
<thead>
<tr>
<th>Prediction method</th>
<th>Once daily group (n = 9)</th>
<th>Twice daily group (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Modified projected adult height</td>
<td>146.7 (6.0)</td>
<td>151.5 (6.9)</td>
</tr>
<tr>
<td>Modified index of potential height, including RUS bone age</td>
<td>146.9 (3.7)</td>
<td>151.2 (5.6)</td>
</tr>
<tr>
<td>Bayley and Pinneau prediction of adult height</td>
<td>145.8 (5.2)</td>
<td>151.5 (6.9)</td>
</tr>
<tr>
<td>Turner’s specific FH prediction method, including RUS bone age</td>
<td>147.4 (5.7)</td>
<td>151.4 (6.4)</td>
</tr>
<tr>
<td>Average of the four predictions</td>
<td>146.7 (4.9)</td>
<td>151.4 (6.3)</td>
</tr>
</tbody>
</table>

Results are mean (SD) centimetres.

FH, Final height; RUS, radius, ulna, short bones.

Results

GROWTH EVALUATION

Table 1 lists the baseline (after the second randomisation) clinical data of the girls. As described in a previous paper, at baseline, there were no relevant differences between the two groups for any of the variables. Before treatment, the mean chronological age, bone age, and HSDSCA values of the girls in the twice daily group were slightly (not significantly) higher compared with those in the once daily group.

Table 2 shows the mean predicted adult height according to the four different prediction methods. For both groups the differences between the four predictions were small and not significantly different from zero. Therefore, we used for further analyses the average of the four predictions as the predicted adult height.

Table 3 shows the clinical data at final height. The difference in final height between the two treatment groups was 2.2 cm in favour of the twice daily group, but this difference was not significant. However, after adjustment for baseline variables (RUS BA and the predicted adult height), the mean final height of the twice daily group minus the mean final height of the once daily group was −1.2 cm (95% confidence interval, −3.8 to 1.4). Thus, the once daily group had a slightly better growth response on GH treatment until final height compared with the twice daily group, but this difference was not significant. For both treatment groups, final height was significantly higher than the predicted adult height at start (p < 0.001). Sixteen of the 19 girls have reached a final height > 150 cm, and five of them even had a final height > 160 cm.

The duration of GH treatment (from start of GH treatment until height velocity < 1 cm/six months) was significantly shorter in the twice daily group compared with the once daily group, even after adjustment for RUS BA at baseline (p < 0.02). No significant difference in bone maturation from the start of GH treatment until final height was found between the once daily and twice daily groups: bone age to chronological age ratio (year/year) was 0.7 v 0.8, respectively.

At final height, HSDS (RvW) and HSDS (DSD) were significantly increased compared with baseline in the once daily group (p < 0.001). In the twice daily group, both HSDS (RvW) and HSDS (DSD) were increased compared with baseline, but only the increase in HSDS (RvW) was significant (p < 0.001). The increase in HSDSCA (RvW) and DSD were higher in the once daily group compared with the twice daily group, but this difference was not significant. All girls exceeded their adult height prediction (final height gain range, 1.6–12.3 cm). Thirteen of the 19 girls had a final height gain > 5.0 cm.

RELATIONS WITH GROWTH RESPONSE

Multiple linear regression analyses of the final height gain after adjustment for treatment group revealed a significant negative correlation with baseline RUS BA ($\beta = 1.6$; p = 0.021) (fig 1) and a significant positive correlation with increase in HSDSCA (DSD) in the first year of GH treatment ($\beta = 7.8$; p = < 0.0001) (fig 2). Final height gain was not significantly related to pretreatment chronological age, HSDS (DSD), target height, plasma IGF-I, IGFBP3, IGF-I to IGFBP3 ratio, GHBP, or maximum GH levels after provocation, nor to the change after six months of GH treatment in plasma IGF-I, IGFBP3, IGF-I to IGFBP3 ratio, and GHBP.

Pubertal development

Tanner breast stage development was not significantly different between the once daily and twice daily groups: at the end of GH treatment, the distribution of the number of girls with Tanner stages B1 to B5 was 1, 0, 3, 3, 2 and 0, 2, 2, 4, 2, respectively. At the end of GH treatment, six girls had experienced their menarche.

Table 3  Clinical data at final height

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>n</th>
<th>Final height (cm)</th>
<th>Predicted adult height (cm)</th>
<th>Months of GH treatment</th>
<th>Increase HSDSCA (RvW)</th>
<th>Increase HSDS (DSD)</th>
<th>Final height gain (cm)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Once daily</td>
<td>9</td>
<td>154.3 (5.2)</td>
<td>146.7 (4.9)</td>
<td>48.0 (6.7)</td>
<td>1.5 (0.6)</td>
<td>1.0 (0.5)</td>
<td>7.6 (2.3)</td>
</tr>
<tr>
<td>Twice daily</td>
<td>10</td>
<td>156.5 (5.6)</td>
<td>151.4 (6.3)</td>
<td>38.4 (8.1)</td>
<td>1.2 (0.6)</td>
<td>0.4 (0.7)</td>
<td>5.1 (3.2)</td>
</tr>
<tr>
<td>Total</td>
<td>19</td>
<td>155.5 (5.4)</td>
<td>149.2 (6.0)</td>
<td>42.9 (8.8)</td>
<td>1.3 (0.6)</td>
<td>0.8 (0.7)</td>
<td>6.3 (3.0)</td>
</tr>
</tbody>
</table>

Results are mean (SD).

*Final height minus predicted adult height.

HSDSCA, height standard deviation score for chronological age; RvW, Roede van Wieringen references for healthy Dutch girls; DSD: Dutch–Swedish–Danish references for girls with Turner’s syndrome.
Growth hormone in Turner’s syndrome

Figure 1  Relation between the final height gain (cm) and the bone age (RUS BA) (years) at start of the GH treatment ($\beta = -1.6; p = 0.021$).

Figure 2  Relation between the final height gain (cm) and the increase in $\text{HSDSCA}_{\text{DSD}}$ (DSD) in the first year of GH treatment ($\beta = 7.8; p = < 0.0001$)

SIDE EFFECTS
No clinically relevant side effects attributable to GH were noted.

Discussion
Division of the total daily GH dose (6 IU/m$^2$/day) into two thirds in the evening and one third in the morning is not advantageous over the once daily GH regimen with respect to final height gain. Final height tended towards a higher mean value with once daily GH compared with twice daily GH after correction for baseline variables, but a significant difference between the two groups was not found. The mean corrected difference in final height (twice daily minus once daily) was $-1.2$ cm with a 95% confidence interval between $-3.8$ and $+1.4$ cm in favour of the once daily group. The absence of a significant difference in final height between the once daily and twice daily groups might be caused by lack of power as a result of the relatively small numbers of girls in both groups. However, we have proved that the effect of GH treatment of more than 1.4 cm in favour of the twice daily group can be excluded with 95% confidence.

Our final height data are in line with the two year results. The growth response after two years’ GH on a total daily dose of 6 IU/m$^2$ in combination with 0.05 µg ethinyl oestradiol/kg/day was not significantly different between the two GH injection regimens. However, height velocity in the second year of the study and the change in $\text{HSDSCA}_{\text{DSD}}$ during the second year and after two years of study was higher in the once daily group compared with the twice daily group. Thus, a tendency in favour of once daily injections was already seen in the first two years of treatment.

The 24 hour GH profiles in 10 of these girls showed that the mean area under the curve (AUC) was 3.1 times higher for the night time period compared with the day time period in the girls receiving twice daily GH treatment, although the GH dose at bedtime was only twice as high as the morning dose. In addition, the mean AUC values for the night time period were 1.9 times higher for the once daily treatment than the twice daily one, while the GH dose at bedtime was only 1.5 times higher in the once daily group. These results suggest a difference in GH bioavailability and are in line with the trend towards a better final height gain in the once daily group.

To our knowledge, our study is the only one in which girls with Turner’s syndrome have received twice daily injections of GH until final height. In a study in girls with Turner’s syndrome, comparing a once daily regimen with a twice daily regimen in which an equal division of a daily GH dose (25 IU/m$^2$/week) was made, the change in height velocity in the first year of treatment was somewhat higher in the once daily group (mean (SD), 3.5 (1.3) cm/year) compared with the twice daily group (mean (SD), 2.7 (1.8) cm/year), but also in this study the difference was not significant.

Apart from the small and non-significant difference in final height gain between the two groups, the duration of the GH treatment in our study was significantly longer in the once daily group than in the twice daily group, even after adjustment for bone age at baseline. Apart from the possibility that these differences are the result of a type I error, one can speculate that the effect of the twice daily GH regimen is comparable with the effect of a lower GH dose (for example, as a result of lower GH bioavailability). As a result, this causes a worse growth response than the once daily GH regimen. Consequently, this might cause an earlier decrease in height velocity, resulting in an earlier discontinuation of GH treatment, and a lower final height gain. Another explanation might be a more pronounced effect of the twice daily regimen on bone maturation than on height velocity compared with the once daily regimen. However, no significant difference in bone maturation between the two groups was found.

The final height gain was, independent of treatment group, negatively related with baseline RUS BA. Therefore, the large individual differences in final height gain could partly be explained by the interindividual difference in RUS BA at baseline. From a statistical point of view, it is important to mention that baseline RUS BA was only moderately and not significantly correlated ($r = 0.26; p = 0.278$) with the adult height prediction at the start. Accordingly, this relation with final height gain cannot be explained by regression to the mean. In addition, final height gain was positively related with the increase in $\text{HSDSCA}_{\text{DSD}}$ (DSD) in the first year of GH treatment.

Downloaded from adc.bmj.com on 6 December 2006
Table 4 Final height in girls with Turner’s syndrome treated with growth hormone

<table>
<thead>
<tr>
<th>Reference</th>
<th>n</th>
<th>Age start (years)</th>
<th>Dose (IU/m²/week)</th>
<th>Ethinyl oestradiol</th>
<th>Oxandrolone dose (mg/kg/day)</th>
<th>FH gain over (mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt; 12</td>
<td>2 years GH: 24</td>
<td>Mean 14.5</td>
<td>2-5 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt; 2 years GH: 36</td>
<td></td>
<td>Mean 13.3</td>
<td>5-20 µg/day</td>
<td>3.0</td>
</tr>
<tr>
<td>van den Broeck et al (1995)</td>
<td>78</td>
<td>Mean 11.7–14.6</td>
<td>~ 21–27</td>
<td>&gt; 1 year: 4.3</td>
<td>None</td>
<td>3.3</td>
</tr>
<tr>
<td>Taback et al (1996)</td>
<td>17</td>
<td>Median 12.4</td>
<td>~ 29</td>
<td>Mean 13.3</td>
<td>5-20 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>Nilsson et al (1996)</td>
<td>14</td>
<td>None</td>
<td></td>
<td>Mean 13.3-15.5</td>
<td>5-20 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>&gt; 1 year: no GH</td>
<td>0.05</td>
<td>Mean 15.3-16.4</td>
<td>100 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>&gt; 1 year: no GH</td>
<td>0.05</td>
<td>Mean 13.3</td>
<td>100 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>16</td>
<td>16</td>
<td>&gt; 21</td>
<td>0.05</td>
<td>Mean 15.1</td>
<td>100 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>15</td>
<td>15</td>
<td>&gt; 21</td>
<td>0.05</td>
<td>Mean 12.3</td>
<td>100 µg/day</td>
<td>3.3</td>
</tr>
<tr>
<td>Rosenfeld et al (1999)</td>
<td>30</td>
<td>9.3</td>
<td>~31.5</td>
<td>Mean BA 14</td>
<td>–</td>
<td>10.4</td>
</tr>
<tr>
<td>Haeusler et al (1996)</td>
<td>20</td>
<td>7.3–16.4</td>
<td>0.05–2.5 years: 12–18,</td>
<td>Mean BA 13.3</td>
<td>In 18 months from 50 to 200</td>
<td>9.3</td>
</tr>
</tbody>
</table>

BP, Bayley Pinneau prediction method; (m)PAH, (modified) projected adult height.

clusion, a “younger bone age” at baseline and a higher increase in HSDDSCA (DSD) in the first year of GH treatment predict a higher final height gain after GH treatment.

Previous publications on the effect of GH treatment on final height in girls with Turner’s syndrome are summarised in table 4. The only other study in which girls with Turner’s syndrome used a GH dose comparable with the dose in our study is described by Massa et al. The lower final height gain in that study compared with our results can be explained by the lower GH injection frequency and/or total GH dose each week in the first two weeks of the study. Other studies in which “relatively old” girls were treated with lower GH doses (without oxandrolone) are quite disappointing. In the published studies in which girls with Turner’s syndrome started GH treatment at a younger age and/or were treated with GH in combination with oxandrolone, the gain in height was comparable with or better than that of our study. The effect of a relatively short period of higher dose GH treatment on final height gain seems to be comparable with the effect of the lower dose regimen in the subsequent years of the treatment in the “young starting ethinyl oestriol group” and not by a significant acceleration of the bone maturation in the first three years of GH treatment. Other GH (with or without oxandrolone) studies in which the induction of puberty was delayed until the epiphysial plates were almost closed, showed no obvious better final height gain than that of our study, in which low dose oestrogens were combined with a relatively high GH dose. Despite the low oestrogen dose, apart from one girl who was still prepubertal, all girls had breast development at the end of GH treatment. Sixteen of 19 girls had breast stage 3 or more and six girls had experienced their menarche. We consider it of utmost importance for the psychological well being of the girls to have their pubertal development in conformity with their peers.

Conclusions

Division of the total daily GH dose of 6 IU/m²/ day into two thirds in the evening and one third in the morning is not advantageous over the once daily GH regimen with respect to final height gain. In addition, treatment with a GH dose of 6 IU/m²/day in combination with low dose oestrogens can result in a significant increase in adult height in girls with Turner’s syndrome, even if they start GH treatment at a relatively late age.

We gratefully acknowledge the support of A van de Wiel and I van Slobbe in performing this study. This study was supported by Novo Nordisk A/S, Denmark.

Growth hormone in Turner’s syndrome


